Hung Lab

We are facing an incredible challenge in the realm of infectious diseases that has been brought on by the convergence of three current phenomena – newly emerging infectious organisms, a global crisis in antibiotic resistance, and the threat of bioterrorism. A response to this challenge requires a renewed devotion to understanding the underlying mechanisms involved in infection and an increased commitment to the discovery of new antibiotics.

The goal of research in the Hung Lab is to understand in vivo mechanisms of bacterial pathogenesis by studying pathogen-host interactions. By merging the fields of chemical genetics and bacterial genetics/genomics, we hope to provide insight into possible new paradigms for addressing infectious diseases.

Despite recent, largely genetic, technical advances in the field of in vivo pathogen-host interactions, many important questions related to the mechanisms of bacterial pathogenesis remain unanswered, in part because of the inability of in vitro conditions to accurately mimic in vivo ones. The newly developing field of chemical genetics offers a novel and promising approach to studying these mechanisms, thus complementing traditional genetic studies. Chemical genetics uses small, organic molecules as specific tools to conditionally induce a phenotype by activating or inhibiting specific protein targets, thus allowing the manipulation of relevant pathways in vitro and in vivo, on very short time scales.

In concert with taking a chemical biological approach to pathogenesis, our lab is interested in developing powerful genomic approaches to systematically and comprehensively identify all bacterial genes required for infection and to facilitate rapid identification of small molecule targeted pathways and interactions. Using small molecules that we identify and develop from high-throughput, forward phenotypic screens and arrayed, knockout libraries of different pathogens, including Vibrio cholerae, Pseudomonas aeruginosa and Mycobacterium tuberculosis, we hope to identify new approaches to disease intervention.

Hung Lab Team

Julian Braxton
Undergraduate Student
Nicole Chumbler
Research Fellow
Anne Clatworthy
Research Scientist II
Senya Combs
Research Tech I
Christoph Ernst
Research Fellow
Li Li
Sr. Research Technologist
Margarita Parada
Research Fellow
Cristina Penaranda
Research Fellow
Brad Poulsen
Research Fellow
Carlos Rodriguez-Osorio
Research Fellow
Keith Romano
Research Fellow
Anna Zagieboylo
Research Technician I
Roby Bhattacharyya
Nikhilesh Chand
Imran Ghare
Erik Hett
Chemical Biology Senior Scientist, Pfizer
Tomohiko Kawate
Christina Lalani
Jenny Lee
David Miranda
Daniel Oh
Sarah Osmulski
Alexandra Panov
Pratik Shah
Louise Slater
Tiantian White-Zhou

Hung Lab Research

Deborah Hung is a physician-scientist combining chemical and genomic approaches to define host-pathogen interactions and to reveal the critical pressure points of infectious disease. By deploying small organic molecules on a genome-wide scale to both perturb and understand bacterial infection, she hopes to identify new therapeutic prospects for a variety of devastating pathogens, including Vibrio cholerae, Pseudomonas aeruginosa and Mycobacterium tuberculosis.

Deborah received her Ph.D. in chemistry from Harvard University, where she worked in Stuart Schreiber’s laboratory to characterize the chemical and biological properties of discodermolide, a small molecule isolated from marine sponges that stabilizes microtubules. More recently, she pursued her postdoctoral research in the laboratory of John Mekalanos at Harvard Medical School, using a high-throughput chemical screen to identify a small molecule that inhibits two major virulence factors of Vibrio cholerae, a gram-negative bacterium that causes an acute intestinal diarrhea. When given orally, the inhibitor can protect mice from the effects of V. cholerae infection. Although cholera outbreaks are relatively rare in the United States, the disease is epidemic in many non-industrialized countries where water sanitation is poor.

Deborah received her medical degree from Harvard Medical School and completed a residency in internal medicine and fellowships in infectious disease and critical care medicine at Brigham and Women’s Hospital and Massachusetts General Hospital. Currently, she holds positions as an infectious disease physician at Brigham and Women’s Hospital and Massachusetts General Hospital and an attending critical care physician in the Medical Intensive Care Unit at Brigham and Women’s Hospital.